https://cfdalaw.blog/2021/10/27/fda-provides-update-on-its-efforts-on-the-china-requirement-that-all-facilities-importing-food-into-china-must-be-registered-by-january-1-2022/2021-10-27T20:28:24+00:00monthlyhttps://cfdalaw.blog/2021/06/13/168/2021-06-13T17:38:10+00:00monthlyhttps://cfdalaw.blog/2021/05/13/new-access-to-chinas-pharmaceutical-market-through-the-greater-bay-area-program/2021-05-13T13:38:30+00:00monthlyhttps://cfdalaw.blog/2020/11/02/china-adopts-new-biosecurity-law-with-continuing-emphasis-on-protecting-security-of-chinese-human-genetic-resources/2020-11-02T15:20:56+00:00monthlyhttps://cfdalaw.blog/2020/10/28/chinas-nmpa-publishes-key-technical-guidelines-accepting-foreign-clinical-trial-data-for-new-drugs/2020-10-28T23:31:16+00:00monthlyhttps://cfdalaw.blog/2020/10/18/chinas-new-hatch-waxman-formally-adopted-yet-still-time-to-comment-on-details/2020-10-18T15:14:07+00:00monthlyhttps://cfdalaw.blog/2020/10/14/chinas-drug-regulator-seeking-comments-for-its-updated-regulation-for-drug-recalls/2020-10-14T17:35:17+00:00monthlyhttps://cfdalaw.blog/2020/09/16/the-other-shoe-has-dropped-chinas-nmpa-releases-proposal-for-modified-hatch-waxman-following-patent-law-reform/2020-09-16T12:32:58+00:00monthlyhttps://cfdalaw.blog/2020/07/06/chinas-hatch-waxman-as-revealed-in-new-amended-patent-law/2020-07-06T16:11:04+00:00monthlyhttps://cfdalaw.blog/2020/01/21/navigating-chinas-expanding-life-science-market-review-for-2019/2020-01-21T18:56:55+00:00monthlyhttps://cfdalaw.blog/2020/01/21/china-is-to-establish-pharmaceutical-patent-linkage-and-restoration-under-us-china-trade-deal/2020-01-21T18:55:25+00:00monthlyhttps://cfdalaw.blog/2019/05/20/china-survival-of-the-fittest-or-cheapest/2019-05-20T14:31:44+00:00monthlyhttps://cfdalaw.blog/2019/04/01/china-drug-regulatory-adds-additional-30-new-drugs-to-its-urgently-needed-list/2019-04-01T20:39:35+00:00monthlyhttps://cfdalaw.blog/2019/01/08/china-proposes-patent-term-restoration-for-new-drugs-and-higher-damages-for-intellectual-property-infringement-in-its-patent-law/2019-01-09T15:16:42+00:00monthlyhttps://cfdalaw.blog/2018/12/31/china-takes-significant-steps-to-consolidate-generic-drug-industry-and-lower-prices/2018-12-31T19:42:40+00:00monthlyhttps://cfdalaw.blog/2018/05/02/china-breaking-down-the-great-wall/2018-05-02T19:48:00+00:00monthlyhttps://cfdalaw.blog/2018/05/02/china-drug-administration-publishes-a-key-draft-guidance-on-data-exclusivity/2018-05-02T19:45:54+00:00monthlyhttps://cfdalaw.blog/2018/03/05/cfda-continues-to-expand-oversea-inspection/2018-03-05T09:40:19+00:00monthlyhttps://cfdalaw.blog/2018/01/25/the-journey-begins/2018-01-27T21:09:21+00:00monthlyhttps://cfdalaw.blog/2018/01/27/a-primer-on-dairy-exports-to-china/2018-01-27T19:20:57+00:00monthlyhttps://cfdalaw.blog/contact/https://cfdalaw.blog/wp-content/uploads/2018/01/person-smartphone-office-table.jpegPlaceholder Image2018-01-25T14:42:41+00:00weekly0.6https://cfdalaw.blog/blog/2018-01-25T14:42:41+00:00weekly0.6https://cfdalaw.blogdaily1.02021-10-27T20:28:24+00:00